fluconazole has been researched along with Leishmaniasis, Visceral in 10 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Leishmaniasis, Visceral: A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have previously shown that 3-nitro-1H-1,2,4-triazole-based arylamides and arylsulfonamides demonstrate significant activity in vitro against Trypanosoma cruzi, the causative parasite of Chagas disease." | 3.80 | Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents. ( Bloomer, WD; Kaiser, M; Papadopoulou, MV; Rosenzweig, HS; Wilkinson, SR, 2014) |
| " To combat this situation, leishmanicidal efficacy of already marketed standard antifungal drug, fluconazole under the approach of "therapeutic switching" in combination with standard antileishmanial drug, miltefosine, and a potent immunomodulator agent, picroliv, were evaluated in hamsters infected with Leishmania donovani." | 1.37 | Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator--picroliv. ( Gupta, S; Sane, SA; Shakya, N, 2011) |
| "Standard treatments for visceral leishmaniasis (antimonials, amphotericin B and pentamidine) pose several problems." | 1.33 | Successful treatment of visceral leishmaniasis with fluconazole and allopurinol in a patient with renal failure. ( Colakoglu, M; Colakoglu, NY; Yaylali, GF; Yilmaz, M, 2006) |
| "Standard treatments for visceral leishmaniasis (antimonials, amphotericin B and pentamidine) pose several problems." | 1.33 | Successful treatment of visceral leishmaniasis with fluconazole and allopurinol in a patient with renal failure. ( Colakoglu, M; Fidan Yaylali, G; Yalcin Colakoglu, N; Yilmaz, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Papadopoulou, MV | 1 |
| Bloomer, WD | 1 |
| Rosenzweig, HS | 1 |
| Wilkinson, SR | 1 |
| Kaiser, M | 1 |
| Rybniker, J | 1 |
| Goede, V | 1 |
| Mertens, J | 1 |
| Ortmann, M | 1 |
| Kulas, W | 1 |
| Kochanek, M | 1 |
| Benzing, T | 1 |
| Arribas, JR | 1 |
| Fätkenheuer, G | 1 |
| Shakya, N | 1 |
| Sane, SA | 1 |
| Gupta, S | 1 |
| Colakoglu, M | 2 |
| Yaylali, GF | 1 |
| Colakoglu, NY | 1 |
| Yilmaz, M | 2 |
| Fidan Yaylali, G | 1 |
| Yalcin Colakoglu, N | 1 |
| Torrús, D | 1 |
| Boix, V | 1 |
| Massa, B | 1 |
| Portilla, J | 1 |
| Pérez-Mateo, M | 1 |
| Sundar, S | 2 |
| Singh, VP | 1 |
| Agrawal, NK | 1 |
| Gibbs, DL | 1 |
| Murray, HW | 1 |
| Kumar, P | 1 |
| Makharia, M | 1 |
| Goyal, A | 1 |
| Rogers, M | 1 |
| Gibbs, D | 1 |
| Murray, H | 1 |
| Jha, BB | 1 |
| Al-Abdely, HM | 1 |
| Graybill, JR | 1 |
| Loebenberg, D | 1 |
| Melby, PC | 1 |
1 review available for fluconazole and Leishmaniasis, Visceral
| Article | Year |
|---|---|
Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure--a case report and brief review of the literature.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Drug Therapy, Com | 2010 |
2 trials available for fluconazole and Leishmaniasis, Visceral
| Article | Year |
|---|---|
Atovaquone alone or with fluconazole as oral therapy for Indian kala-azar.
Topics: Adolescent; Adult; Animals; Antifungal Agents; Antiprotozoal Agents; Atovaquone; Child; Child, Presc | 1998 |
Fluconazole in visceral leishmaniasis.
Topics: Adolescent; Antifungal Agents; Child; Child, Preschool; Female; Fluconazole; Humans; India; Leishman | 1998 |
7 other studies available for fluconazole and Leishmaniasis, Visceral
| Article | Year |
|---|---|
Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
Topics: Amides; Apoptosis; Blood Platelets; Cells, Cultured; Chagas Disease; Flow Cytometry; Heterocyclic Co | 2014 |
Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator--picroliv.
Topics: Animals; Antiprotozoal Agents; Cinnamates; Cricetinae; Drug Therapy, Combination; Fluconazole; Glyco | 2011 |
Successful treatment of visceral leishmaniasis with fluconazole and allopurinol in a patient with renal failure.
Topics: Allopurinol; Antifungal Agents; Antimetabolites; Diabetic Nephropathies; Fluconazole; Humans; Leishm | 2006 |
Successful treatment of visceral leishmaniasis with fluconazole and allopurinol in a patient with renal failure.
Topics: Allopurinol; Animals; Antimetabolites; Antiprotozoal Agents; Diabetic Nephropathies; Drug Therapy, C | 2006 |
Fluconazole plus allopurinol in treatment of visceral leishmaniasis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Allopurinol; Antifungal Agents; Antimetabolites; Bone Mar | 1996 |
Treatment of kala-azar with oral fluconazole.
Topics: Administration, Oral; Adolescent; Adult; Child; Child, Preschool; Drug Administration Schedule; Fema | 1996 |
Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases.
Topics: Amphotericin B; Animals; Fluconazole; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, | 1999 |